Financhill
Buy
73

WRBY Quote, Financials, Valuation and Earnings

Last price:
$25.20
Seasonality move :
-22.2%
Day range:
$23.27 - $25.30
52-week range:
$11.35 - $25.36
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.06x
P/B ratio:
9.00x
Volume:
3.6M
Avg. volume:
1.7M
1-year change:
99.05%
Market cap:
$3B
Revenue:
$669.8M
EPS (TTM):
-$0.27

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
WRBY
Warby Parker
$190.1M $0.05 15.41% -- $22.23
ATR
AptarGroup
$923.9M $1.42 2.81% 36.77% $148.43
CATX
Perspective Therapeutics
$237.9K -$0.20 -- -70.12% --
DXR
Daxor
-- -- -- -- --
POCI
Precision Optics
-- -- -- -- --
SMTI
Sanara MedTech
$20.7M -- 26.63% -- $44.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
WRBY
Warby Parker
$25.18 $22.23 $3B -- $0.00 0% 4.06x
ATR
AptarGroup
$158.18 $148.43 $10.5B 31.76x $0.45 1.09% 2.99x
CATX
Perspective Therapeutics
$2.85 -- $192.6M -- $0.00 0% 15.39x
DXR
Daxor
$8.35 -- $40.4M 27.81x $0.00 0% 15.44x
POCI
Precision Optics
$5.21 -- $33.1M -- $0.00 0% 1.68x
SMTI
Sanara MedTech
$33.62 $44.00 $293.9M -- $0.00 0% 3.64x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
WRBY
Warby Parker
-- 4.316 -- 1.94x
ATR
AptarGroup
29.76% -0.041 10.09% 1.00x
CATX
Perspective Therapeutics
-- -5.312 -- --
DXR
Daxor
4.81% 0.050 3.66% --
POCI
Precision Optics
19.99% 2.078 7.15% 0.70x
SMTI
Sanara MedTech
43.05% 1.849 11.39% 1.99x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
WRBY
Warby Parker
$104.9M -$6.6M -10.25% -10.25% -3.44% $13.1M
ATR
AptarGroup
$350.8M $142.2M 9.63% 14.16% 15.77% $149.5M
CATX
Perspective Therapeutics
-- -$18.6M -- -- -- -$26.3M
DXR
Daxor
-- -- 5.09% 5.22% -- --
POCI
Precision Optics
$1.1M -$1.2M -27.98% -34.86% -29.71% -$346.7K
SMTI
Sanara MedTech
$19.7M -$1.8M -14.62% -19.67% -9.02% $2M

Warby Parker vs. Competitors

  • Which has Higher Returns WRBY or ATR?

    AptarGroup has a net margin of -2.12% compared to Warby Parker's net margin of 11%. Warby Parker's return on equity of -10.25% beat AptarGroup's return on equity of 14.16%.

    Company Gross Margin Earnings Per Share Invested Capital
    WRBY
    Warby Parker
    54.49% -$0.03 $336.8M
    ATR
    AptarGroup
    38.58% $1.48 $3.6B
  • What do Analysts Say About WRBY or ATR?

    Warby Parker has a consensus price target of $22.23, signalling downside risk potential of -11.71%. On the other hand AptarGroup has an analysts' consensus of $148.43 which suggests that it could grow by 18.85%. Given that AptarGroup has higher upside potential than Warby Parker, analysts believe AptarGroup is more attractive than Warby Parker.

    Company Buy Ratings Hold Ratings Sell Ratings
    WRBY
    Warby Parker
    6 5 0
    ATR
    AptarGroup
    3 4 0
  • Is WRBY or ATR More Risky?

    Warby Parker has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison AptarGroup has a beta of 0.577, suggesting its less volatile than the S&P 500 by 42.257%.

  • Which is a Better Dividend Stock WRBY or ATR?

    Warby Parker has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AptarGroup offers a yield of 1.09% to investors and pays a quarterly dividend of $0.45 per share. Warby Parker pays -- of its earnings as a dividend. AptarGroup pays out 36.45% of its earnings as a dividend. AptarGroup's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios WRBY or ATR?

    Warby Parker quarterly revenues are $192.4M, which are smaller than AptarGroup quarterly revenues of $909.3M. Warby Parker's net income of -$4.1M is lower than AptarGroup's net income of $100M. Notably, Warby Parker's price-to-earnings ratio is -- while AptarGroup's PE ratio is 31.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Warby Parker is 4.06x versus 2.99x for AptarGroup. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    WRBY
    Warby Parker
    4.06x -- $192.4M -$4.1M
    ATR
    AptarGroup
    2.99x 31.76x $909.3M $100M
  • Which has Higher Returns WRBY or CATX?

    Perspective Therapeutics has a net margin of -2.12% compared to Warby Parker's net margin of --. Warby Parker's return on equity of -10.25% beat Perspective Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    WRBY
    Warby Parker
    54.49% -$0.03 $336.8M
    CATX
    Perspective Therapeutics
    -- -$0.21 --
  • What do Analysts Say About WRBY or CATX?

    Warby Parker has a consensus price target of $22.23, signalling downside risk potential of -11.71%. On the other hand Perspective Therapeutics has an analysts' consensus of -- which suggests that it could grow by 466.67%. Given that Perspective Therapeutics has higher upside potential than Warby Parker, analysts believe Perspective Therapeutics is more attractive than Warby Parker.

    Company Buy Ratings Hold Ratings Sell Ratings
    WRBY
    Warby Parker
    6 5 0
    CATX
    Perspective Therapeutics
    0 0 0
  • Is WRBY or CATX More Risky?

    Warby Parker has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.129, suggesting its more volatile than the S&P 500 by 12.894%.

  • Which is a Better Dividend Stock WRBY or CATX?

    Warby Parker has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Warby Parker pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios WRBY or CATX?

    Warby Parker quarterly revenues are $192.4M, which are larger than Perspective Therapeutics quarterly revenues of --. Warby Parker's net income of -$4.1M is higher than Perspective Therapeutics's net income of -$15.1M. Notably, Warby Parker's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Warby Parker is 4.06x versus 15.39x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    WRBY
    Warby Parker
    4.06x -- $192.4M -$4.1M
    CATX
    Perspective Therapeutics
    15.39x -- -- -$15.1M
  • Which has Higher Returns WRBY or DXR?

    Daxor has a net margin of -2.12% compared to Warby Parker's net margin of --. Warby Parker's return on equity of -10.25% beat Daxor's return on equity of 5.22%.

    Company Gross Margin Earnings Per Share Invested Capital
    WRBY
    Warby Parker
    54.49% -$0.03 $336.8M
    DXR
    Daxor
    -- -- $34.3M
  • What do Analysts Say About WRBY or DXR?

    Warby Parker has a consensus price target of $22.23, signalling downside risk potential of -11.71%. On the other hand Daxor has an analysts' consensus of -- which suggests that it could grow by 179.94%. Given that Daxor has higher upside potential than Warby Parker, analysts believe Daxor is more attractive than Warby Parker.

    Company Buy Ratings Hold Ratings Sell Ratings
    WRBY
    Warby Parker
    6 5 0
    DXR
    Daxor
    0 0 0
  • Is WRBY or DXR More Risky?

    Warby Parker has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Daxor has a beta of -0.508, suggesting its less volatile than the S&P 500 by 150.824%.

  • Which is a Better Dividend Stock WRBY or DXR?

    Warby Parker has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Daxor offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Warby Parker pays -- of its earnings as a dividend. Daxor pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios WRBY or DXR?

    Warby Parker quarterly revenues are $192.4M, which are larger than Daxor quarterly revenues of --. Warby Parker's net income of -$4.1M is higher than Daxor's net income of --. Notably, Warby Parker's price-to-earnings ratio is -- while Daxor's PE ratio is 27.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Warby Parker is 4.06x versus 15.44x for Daxor. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    WRBY
    Warby Parker
    4.06x -- $192.4M -$4.1M
    DXR
    Daxor
    15.44x 27.81x -- --
  • Which has Higher Returns WRBY or POCI?

    Precision Optics has a net margin of -2.12% compared to Warby Parker's net margin of -31.24%. Warby Parker's return on equity of -10.25% beat Precision Optics's return on equity of -34.86%.

    Company Gross Margin Earnings Per Share Invested Capital
    WRBY
    Warby Parker
    54.49% -$0.03 $336.8M
    POCI
    Precision Optics
    26.62% -$0.21 $12.7M
  • What do Analysts Say About WRBY or POCI?

    Warby Parker has a consensus price target of $22.23, signalling downside risk potential of -11.71%. On the other hand Precision Optics has an analysts' consensus of -- which suggests that it could fall by --. Given that Warby Parker has higher upside potential than Precision Optics, analysts believe Warby Parker is more attractive than Precision Optics.

    Company Buy Ratings Hold Ratings Sell Ratings
    WRBY
    Warby Parker
    6 5 0
    POCI
    Precision Optics
    0 0 0
  • Is WRBY or POCI More Risky?

    Warby Parker has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Precision Optics has a beta of 0.291, suggesting its less volatile than the S&P 500 by 70.901%.

  • Which is a Better Dividend Stock WRBY or POCI?

    Warby Parker has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Precision Optics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Warby Parker pays -- of its earnings as a dividend. Precision Optics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios WRBY or POCI?

    Warby Parker quarterly revenues are $192.4M, which are larger than Precision Optics quarterly revenues of $4.2M. Warby Parker's net income of -$4.1M is lower than Precision Optics's net income of -$1.3M. Notably, Warby Parker's price-to-earnings ratio is -- while Precision Optics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Warby Parker is 4.06x versus 1.68x for Precision Optics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    WRBY
    Warby Parker
    4.06x -- $192.4M -$4.1M
    POCI
    Precision Optics
    1.68x -- $4.2M -$1.3M
  • Which has Higher Returns WRBY or SMTI?

    Sanara MedTech has a net margin of -2.12% compared to Warby Parker's net margin of -13.19%. Warby Parker's return on equity of -10.25% beat Sanara MedTech's return on equity of -19.67%.

    Company Gross Margin Earnings Per Share Invested Capital
    WRBY
    Warby Parker
    54.49% -$0.03 $336.8M
    SMTI
    Sanara MedTech
    90.81% -$0.34 $69.5M
  • What do Analysts Say About WRBY or SMTI?

    Warby Parker has a consensus price target of $22.23, signalling downside risk potential of -11.71%. On the other hand Sanara MedTech has an analysts' consensus of $44.00 which suggests that it could grow by 30.88%. Given that Sanara MedTech has higher upside potential than Warby Parker, analysts believe Sanara MedTech is more attractive than Warby Parker.

    Company Buy Ratings Hold Ratings Sell Ratings
    WRBY
    Warby Parker
    6 5 0
    SMTI
    Sanara MedTech
    1 0 0
  • Is WRBY or SMTI More Risky?

    Warby Parker has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sanara MedTech has a beta of 1.574, suggesting its more volatile than the S&P 500 by 57.373%.

  • Which is a Better Dividend Stock WRBY or SMTI?

    Warby Parker has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sanara MedTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Warby Parker pays -- of its earnings as a dividend. Sanara MedTech pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios WRBY or SMTI?

    Warby Parker quarterly revenues are $192.4M, which are larger than Sanara MedTech quarterly revenues of $21.7M. Warby Parker's net income of -$4.1M is lower than Sanara MedTech's net income of -$2.9M. Notably, Warby Parker's price-to-earnings ratio is -- while Sanara MedTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Warby Parker is 4.06x versus 3.64x for Sanara MedTech. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    WRBY
    Warby Parker
    4.06x -- $192.4M -$4.1M
    SMTI
    Sanara MedTech
    3.64x -- $21.7M -$2.9M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret

It’s not often that a company with the scale and…

Will Tyson Foods Stock Bounce Back?
Will Tyson Foods Stock Bounce Back?

Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…

Will Iovance Biotherapeutics Stock Bounce Back?
Will Iovance Biotherapeutics Stock Bounce Back?

Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…

Stock Ideas

Buy
64
Is AAPL Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 42x

Buy
52
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 113x

Buy
55
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Alerts

Buy
61
QMCO alert for Dec 21

Quantum [QMCO] is up 26.28% over the past day.

Sell
46
NUKK alert for Dec 21

Nukkleus [NUKK] is down 22.94% over the past day.

Sell
1
IIPR alert for Dec 21

Innovative Industrial Properties [IIPR] is down 22.7% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock